69776-89-2Relevant academic research and scientific papers
Synthesis of Chiral 5-Aryl-2-oxazolidinones via Halohydrin Dehalogenase-Catalyzed Enantio- and Regioselective Ring-Opening of Styrene Oxides
Wan, Nanwei,Zhou, Xiaoying,Ma, Ran,Tian, Jiawei,Wang, Huihui,Cui, Baodong,Han, Wenyong,Chen, Yongzheng
supporting information, p. 1201 - 1207 (2020/02/05)
An efficient biocatalytic approach for enantio- and regioselective ring-opening of styrene oxides with cyanate was developed by using the halohydrin dehalogenase HheC from Agrobacterium radiobacter AD1, generating the corresponding chiral 5-aryl-2-oxazoli
Method of biocatalytically synthesizing 4-substituted oxazolidinone compound
-
Paragraph 0043; 0044; 0045; 0046, (2019/04/27)
The invention discloses a biocatalytic technology of synthesizing a 4-substituted oxazolidinone compound by carrying out a reaction on a halohydrin dehalogenase catalyzed epoxy compound and cyanate. The reaction takes the epoxy compound as a primer, cyanate as a nucleophilic ring opening reagent and halohydrin dehalogenase which is originated from an Ilumatobacter coccineus strain and has high alpha-offensive ring opening area selectivity as a biocatalyst. The reaction is carried out in a water phase and is mild in reaction condition. The invention is the biocatalytic method of catalyzing theepoxy compound to synthesize the 4-substituted oxazolidinone compound by using the halohydrin dehalogenase for the first time. The method has a wide application prospect in design of an oxazolidinonedrug and green manufacturing aspect thereof.
Therapeutic agent pcnsl (by machine translation)
-
Paragraph 0179, (2016/10/09)
The present invention provides a malignant lymphoma therapeutic or preventive agent that comprises as the active ingredient a compound represented by general formula [1] as defined by (I) or (II), or a pharmaceutically acceptable salt thereof. [1] (I) X is CH or N; R1 is a halogen; R2 is a halogen, H, a cyano, a group represented by general formula [9], [9] an optionally substituted heteroaryl, or the like; R3 is H or a hydroxyl; R4 is H or an alkyl; and R5 is H or an alkyl. (II) X is -CRA, RA is -CORB, RB is an optionally substituted amino, alkoxy, or saturated cyclic amino group; R1 is a halogen; R2 is H; R3is H or a hydroxy; R4 is H or an alkyl; and R5 is H or an alkyl.
AMINOPYRAZINE DERIVATIVE AND MEDICINE
-
Page/Page column 54, (2011/12/12)
The present invention relates to a compound represented by general formula [1] satisfying the following (I) or (II), or a pharmaceutical acceptable salt of the compound. (I) X is CH or N; R1 is a halogen atom,; and R2 is H, a halogen atom, CN, [2], [3], [8], [9], an —O-alkyl, an —O-(saturated ring), etc. [2]: —C(RC)(RD)(RE) (RC to RE each are H, an alkyl, etc.) [3]: —N(RF)(RG) (RF and RG each are H, OH, amino, a (hetero)aryl, etc.) [8]: —C(═O)RL (RL is an alkyl, OH, an alkoxy, amino, etc.) [9]: a (substituted)phenyl; (II) X is >C—C(—O)R3 (R3 is a (substituted)amino, an alkoxy, OH, etc.); R1 is a halogen atom; R2 is H; R3 is H or OH; and R3 and R4 each are H or an alkyl.
